Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content
NEWS #PharmaBuzz
03 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250603416146/en/TriLink-BioTechnologies-and-Quantoom-Biosciences-Sign-License-and-Supply-Agreement-for-CleanCap-mRNA-Capping-Technology
20 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250520267814/en/TriLink-BioTechnologies-debuts-its-first-mRNA-synthesis-kit-with-CleanCap-capping-technology-Celebrates-launch-with-kit-donations-to-top-academic-institutions
15 May 2025
// CONTRACTPHARMA
https://www.contractpharma.com/breaking-news/trilink-international-vaccine-institute-sign-memorandum-of-understanding/
14 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250514331075/en/TriLink-BioTechnologies-and-the-International-Vaccine-Institute-Sign-a-Memorandum-of-Understanding-to-Support-the-Development-of-mRNA-based-Vaccines
03 Feb 2025
// BUSINESSWIRE
28 Jan 2025
// BUSINESSWIRE
Drugs in Development
Details:
TriLink and IVI will collaborate to advance the research and development of mRNA-based vaccines and promote equitable access to essential vaccines and health technologies.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Undisclosed
Sponsor: The International Vaccine Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 14, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : The International Vaccine Institute
Deal Size : Undisclosed
Deal Type : Agreement
TriLink & IVI Sign MoU to Support mRNA Vaccine Development Globally
Details : TriLink and IVI will collaborate to advance the research and development of mRNA-based vaccines and promote equitable access to essential vaccines and health technologies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 14, 2025
Details:
The agreement includes funding for TriLink’s planned expansion of its nucleic acid production capabilities in San Diego, California. TriLink has experienced substantial demand for a wide range of nucleic acid products in support of multiple COVID-19 mRNA vaccine.
Lead Product(s): mRNA COVID-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Vaccine
Sponsor: Department of Defense
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 24, 2022
Lead Product(s) : mRNA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Department of Defense
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement includes funding for TriLink’s planned expansion of its nucleic acid production capabilities in San Diego, California. TriLink has experienced substantial demand for a wide range of nucleic acid products in support of multiple COVID-19 mR...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
May 24, 2022
Details:
EyeGene expected to utilize TriLink’s CleanCap® technology and modified UTP manufactured by TriLink in the production of its EG-COVID mRNA COVID-19 vaccine for clinical trials.
Lead Product(s): EG-COVID mRNA COVID-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Vaccine
Sponsor: EyeGene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 04, 2021
Lead Product(s) : EG-COVID mRNA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : EyeGene
Deal Size : Undisclosed
Deal Type : Collaboration
TriLink BioTechnologies® Extends EyeGene Partnership for COVID-19 Vaccine Development in South Ko...
Details : EyeGene expected to utilize TriLink’s CleanCap® technology and modified UTP manufactured by TriLink in the production of its EG-COVID mRNA COVID-19 vaccine for clinical trials.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
October 04, 2021
Details:
The ChulaCov19 mRNA Covid-19 Vaccine Development Program aims to expand access to an mRNA Covid-19 vaccine in Thailand and other low-to-middle-income countries (LMICs) in Asia.
Lead Product(s): ChulaCov19 mRNA Vaccine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Vaccine
Sponsor: Chula Vaccine Research Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 02, 2021
Lead Product(s) : ChulaCov19 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Chula Vaccine Research Center
Deal Size : Undisclosed
Deal Type : Partnership
TriLink BioTechnologies® Extends Global Support of Covid-19 Vaccine Development into APAC Region ...
Details : The ChulaCov19 mRNA Covid-19 Vaccine Development Program aims to expand access to an mRNA Covid-19 vaccine in Thailand and other low-to-middle-income countries (LMICs) in Asia.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
August 02, 2021
Details:
Under this development partnership, TriLink will use its robust RNA manufacturing capabilities to respond to the global need for vaccine support against COVID-19.
Lead Product(s): Self-Amplifying Rna Vaccine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Vaccine
Sponsor: Imperial College London
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 28, 2020
Lead Product(s) : Self-Amplifying Rna Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Imperial College London
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under this development partnership, TriLink will use its robust RNA manufacturing capabilities to respond to the global need for vaccine support against COVID-19.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
April 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Services
Drug Product Manufacturing
Biologic Drugs
Pharma Service : Drug Product Manufacturing
Category : Biologic Drugs
Sub Category : DNA / RNA
Pharma Service : Drug Product Manufacturing
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
